| Dr Mark Urban Rarick, MD | |
|
3600 N Interstate Ave, Portland, OR 97227-1106 | |
| (503) 285-9321 | |
| Not Available |
| Full Name | Dr Mark Urban Rarick |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 3600 N Interstate Ave, Portland, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114019825 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD00035297 (Washington) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD17194 (Oregon) | Primary |
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
Size matters when it comes to the nucleus of a cell, and now scientists have discovered the signals that control how big the nucleus gets. Nuclear size varies not only among different species, but also in different types of cells in the same species and at different times during development. In addition, cancer cells are known to develop larger nuclei as they become more malignant. Screening for cervical cancer, for example, involves looking for grossly distorted nuclei in cervical cells collected during a Pap smear.
Researchers from the Lille Centre for Infection and Immunity, INRAE and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favors secondary bacterial superinfection.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
Sen. Max Baucus' announcement Tuesday that he will not seek re-election in 2014 could open the door for Sen. Ron Wyden to become the most powerful Senate Democrat on health care issues. Some groups are claiming victory on the retirement announcement while others look at what Wyden could accomplish.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Urban Rarick, MD 18955 Olson Ave, Lake Oswego, OR 97034-7420 Ph: (503) 331-6540 | Dr Mark Urban Rarick, MD 3600 N Interstate Ave, Portland, OR 97227-1106 Ph: (503) 285-9321 |
News Archive
Size matters when it comes to the nucleus of a cell, and now scientists have discovered the signals that control how big the nucleus gets. Nuclear size varies not only among different species, but also in different types of cells in the same species and at different times during development. In addition, cancer cells are known to develop larger nuclei as they become more malignant. Screening for cervical cancer, for example, involves looking for grossly distorted nuclei in cervical cells collected during a Pap smear.
Researchers from the Lille Centre for Infection and Immunity, INRAE and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favors secondary bacterial superinfection.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
Sen. Max Baucus' announcement Tuesday that he will not seek re-election in 2014 could open the door for Sen. Ron Wyden to become the most powerful Senate Democrat on health care issues. Some groups are claiming victory on the retirement announcement while others look at what Wyden could accomplish.
› Verified 2 days ago
Salona Shrestha, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |